APO RESEARCH · REPORT
mRNA Cancer Vaccines and Therapeutics
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Product & engineering
Understand the product.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Selected research
Market Structure
Global mRNA Cancer Vaccines and Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.
The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.
Read the full market overview
Report Includes
This report provides an overview of the global mRNA Cancer Vaccines and Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of mRNA Cancer Vaccines and Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents mRNA Cancer Vaccines and Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the mRNA Cancer Vaccines and Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
mRNA Cancer Vaccines and Therapeutics Segment by Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
mRNA Cancer Vaccines and Therapeutics Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
mRNA Cancer Vaccines and Therapeutics Segment by Application
Infectious Disease
Cancer
Others
mRNA Cancer Vaccines and Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Cancer Vaccines and Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Cancer Vaccines and Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Cancer Vaccines and Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of mRNA Cancer Vaccines and Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Cancer Vaccines and Therapeutics industry.
Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Cancer Vaccines and Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Adeno Carcinomas
- Mucinous Carcinomas
- Adenosquamous Carcinomas
Applications
- Infectious Disease
- Cancer
- Others
Companies covered
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Adeno Carcinomas
- 1.2.3 Mucinous Carcinomas
- 1.2.4 Adenosquamous Carcinomas
- 1.3 Market Analysis by Application
- 1.3.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Infectious Disease
- 1.3.3 Cancer
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global mRNA Cancer Vaccines and Therapeutics Growth Trends by Region
- 1.5.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 mRNA Cancer Vaccines and Therapeutics Market Size by Region (2021-2026)
- 1.5.3 mRNA Cancer Vaccines and Therapeutics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global mRNA Cancer Vaccines and Therapeutics Market Dynamics
- 2.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
- 2.2 mRNA Cancer Vaccines and Therapeutics Industry Drivers
- 2.3 mRNA Cancer Vaccines and Therapeutics Industry Opportunities and Challenges
- 2.4 mRNA Cancer Vaccines and Therapeutics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2021-2026)
- 3.2 Global mRNA Cancer Vaccines and Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global mRNA Cancer Vaccines and Therapeutics Key Company Head office and Area Served
- 3.4 Global mRNA Cancer Vaccines and Therapeutics Company, Product Type & Application
- 3.5 Global mRNA Cancer Vaccines and Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global mRNA Cancer Vaccines and Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 mRNA Cancer Vaccines and Therapeutics Players Market Share by Revenue in 2025
- 3.6.3 2025 mRNA Cancer Vaccines and Therapeutics Tier 1, Tier 2, and Tier 3
4 mRNA Cancer Vaccines and Therapeutics Market by Type
- 4.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021-2032)
- 4.3 Global mRNA Cancer Vaccines and Therapeutics Market Size Share by Type (2021-2032)
5 mRNA Cancer Vaccines and Therapeutics Market by Application
- 5.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2032)
- 5.3 Global mRNA Cancer Vaccines and Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Moderna Therapeutics
- 6.1.1 Moderna Therapeutics Company Information
- 6.1.2 Moderna Therapeutics Business Overview
- 6.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.1.5 Moderna Therapeutics Recent Developments
- 6.2 CureVac
- 6.2.1 CureVac Company Information
- 6.2.2 CureVac Business Overview
- 6.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.2.5 CureVac Recent Developments
- 6.3 Translate Bio
- 6.3.1 Translate Bio Company Information
- 6.3.2 Translate Bio Business Overview
- 6.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.3.5 Translate Bio Recent Developments
- 6.4 BioNTech
- 6.4.1 BioNTech Company Information
- 6.4.2 BioNTech Business Overview
- 6.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.4.5 BioNTech Recent Developments
- 6.5 Sangamo Therapeutics
- 6.5.1 Sangamo Therapeutics Company Information
- 6.5.2 Sangamo Therapeutics Business Overview
- 6.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.5.5 Sangamo Therapeutics Recent Developments
- 6.6 Argos Therapeutics
- 6.6.1 Argos Therapeutics Company Information
- 6.6.2 Argos Therapeutics Business Overview
- 6.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.6.5 Argos Therapeutics Recent Developments
- 6.7 In-Cell-Art
- 6.7.1 In-Cell-Art Company Information
- 6.7.2 In-Cell-Art Business Overview
- 6.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.7.5 In-Cell-Art Recent Developments
- 6.8 eTheRNA
- 6.8.1 eTheRNA Company Information
- 6.8.2 eTheRNA Business Overview
- 6.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.8.5 eTheRNA Recent Developments
- 6.9 Ethris
- 6.9.1 Ethris Company Information
- 6.9.2 Ethris Business Overview
- 6.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.9.5 Ethris Recent Developments
- 6.10 Tiba Biotechnology
- 6.10.1 Tiba Biotechnology Company Information
- 6.10.2 Tiba Biotechnology Business Overview
- 6.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product Portfolio
- 6.10.5 Tiba Biotechnology Recent Developments
7 North America
- 7.1 North America mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 7.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 7.2.1 North America mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021-2026)
- 7.2.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032)
- 7.2.3 North America mRNA Cancer Vaccines and Therapeutics Market Share by Type (2021-2032)
- 7.3 North America mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 7.3.1 North America mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026)
- 7.3.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032)
- 7.3.3 North America mRNA Cancer Vaccines and Therapeutics Market Share by Application (2021-2032)
- 7.4 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country
- 7.4.1 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 7.4.3 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 7.4.4 North America mRNA Cancer Vaccines and Therapeutics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 8.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 8.2.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021-2026)
- 8.2.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032)
- 8.2.3 Europe mRNA Cancer Vaccines and Therapeutics Market Share by Type (2021-2032)
- 8.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 8.3.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026)
- 8.3.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032)
- 8.3.3 Europe mRNA Cancer Vaccines and Therapeutics Market Share by Application (2021-2032)
- 8.4 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country
- 8.4.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 8.4.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 8.4.4 Europe mRNA Cancer Vaccines and Therapeutics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 9.2 China mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 9.2.1 China mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021-2026)
- 9.2.2 China mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032)
- 9.2.3 China mRNA Cancer Vaccines and Therapeutics Market Share by Type (2021-2032)
- 9.3 China mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 9.3.1 China mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026)
- 9.3.2 China mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032)
- 9.3.3 China mRNA Cancer Vaccines and Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 10.2 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 10.2.1 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021-2026)
- 10.2.2 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032)
- 10.2.3 Asia mRNA Cancer Vaccines and Therapeutics Market Share by Type (2021-2032)
- 10.3 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 10.3.1 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026)
- 10.3.2 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032)
- 10.3.3 Asia mRNA Cancer Vaccines and Therapeutics Market Share by Application (2021-2032)
- 10.4 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Country
- 10.4.1 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 10.4.3 Asia mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 10.4.4 Asia mRNA Cancer Vaccines and Therapeutics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst